CGTX
Cognition Therapeutics Inc

3,894
Mkt Cap
$145.57M
Volume
874,383.00
52W High
$3.83
52W Low
$0.2223
PE Ratio
-2.51
CGTX Fundamentals
Price
$1.71
Prev Close
$1.65
Open
$1.64
50D MA
$1.91
Beta
1.43
Avg. Volume
3.64M
EPS (Annual)
-$0.855
P/B
15.25
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade
Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·23d ago
News Placeholder
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the Company or Cognition ) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Globe Newswire·2y ago
News Placeholder
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the Company or Cognition ) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Globe Newswire·2y ago
News Placeholder
B. Riley Reiterates "Buy" Rating for Cognition Therapeutics (NASDAQ:CGTX)
Cognition Therapeutics (NASDAQ:CGTX - Get Free Report)s stock had its "buy" rating restated by investment analysts at B. Riley in a research note issued on Thursday, Benzinga reports. They...
Zolmax·2y ago
News Placeholder
Q4 2023 Cognition Therapeutics Inc Earnings Call Transcript
Related Stocks: NAS:CGTX...
GuruFocus·2y ago
News Placeholder
Cognition Therapeutics reports FY results
Cognition Therapeutics reports FY results...
SeekingAlpha.com: All News·2y ago
News Placeholder
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer's Expected mid-2024 -- On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB in 2H 2024 - - 1Q 2024 Capital...
Globe Newswire·2y ago
News Placeholder
A Preview Of Cognition Therapeutics's Earnings
read more...
Benzinga·2y ago
News Placeholder
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
Conference Call and Live Audio Webcast Scheduled for March 26, 2024PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience...
Globe Newswire·2y ago

Latest CGTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.